Amyloidosis and Waldenström's macroglobulinemia

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Primary systemic amyloidosis is an immunoglobulin light chain disorder, less common than multiple myeloma.
• Waldenström macroglobulinemia (WM) is rarer than amyloidosis, with recent consensus panels defining diagnostic and therapeutic criteria.
• Significant advancements in evaluating treatment responses and novel therapeutic options have emerged for both conditions.

Purpose of the Study:

• To review recent developments in the diagnosis and treatment of primary systemic amyloidosis.
• To cover new consensus criteria and therapeutic strategies for Waldenström macroglobulinemia.
• To provide an updated overview of managing these hematologic disorders from suspicion to treatment.

Main Methods:

• Review of diagnostic approaches for amyloidosis, including suspicion, confirmation, classification, and prognosis assessment.
• Comprehensive review of amyloidosis therapies, from standard regimens to high-dose therapy with stem cell transplantation.
• Discussion of current information on WM, including consensus panel recommendations, prognostic markers, and treatment protocols.

Main Results:

• Recent findings on cardiac biomarkers, presenting features, and free light chain assays aid amyloidosis diagnosis and staging.
• Various standard and high-dose therapies for amyloidosis are discussed, with proposed treatment strategies.
• Updated WM information includes consensus definitions, response criteria, and treatment protocols utilizing novel agents like rituximab.

Conclusions:

• New diagnostic tools and therapeutic options have significantly improved the management of primary systemic amyloidosis.
• Established consensus criteria and emerging treatments offer better management strategies for Waldenström macroglobulinemia.
• This review provides a comprehensive update on the latest advancements in understanding and treating these rare hematologic malignancies.